GHENT, BELGIUM--(Marketwired - May 6, 2013) - Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, proudly announces that GlamSmile China has set in April once again another record month for achieving the highest number of cases, veneer units, and turnover. In April alone 1,320 units were placed generating 4,597,000 million CNY (747,000 USD) (unaudited).
GlamSmile China has studios in Beijing, Shanghai, Wenzhou and Hong Kong and a fifth is under way in Guangzhou. Also Wuhan and Shenzhen are expected to open still this year. Later this year the flagship studio in Beijing will move to CBD area where a new studio of 1.000 m² / 10,700 ft² will accommodate up to 15 operational chairs.
"We are excited about the growth but not at all surprised, as we are setting a new standard for a beautiful smile in China," comments Mr David Lok, Director GlamSmile Asia. "We are recruiting plenty of staff in dentistry, administration, sales. Two more marketing managers have joined our team this month promoting us as the Worldwide Veneer Expert with studios in more than 40 international cities."
Remedent, Inc. creates state-of-the-art dental technologies and marketing concepts. Famous brands are GlamSmile, Remecure, White Boost, Formulation +, and River 8. Headquartered in Belgium, Remedent, Inc. manufactures, markets and distributes its products and concepts to more than 30 countries worldwide. Remedent, Inc. is publicly listed and focuses on B2B, delivering products to the dental professional, as well as B2C approaches, helping consumers to obtain their dream smile through its Smile Consultancy Concept.
Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," "projects," "project," to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent's ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent's business, please refer to the risk factors described in Remedent's filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q.